Compugen Ltd (NAS:CGEN)
$ 1.595 -0.14 (-8.05%) Market Cap: 153.65 Mil Enterprise Value: 68.35 Mil PE Ratio: 0 PB Ratio: 2.50 GF Score: 53/100

Compugen Ltd at JMP Securities Hematology Oncology Summit (Virtual) Transcript

Dec 06, 2022 / 03:20PM GMT
Release Date Price: $1.14 (+3.64%)
Reni Benjamin
JMP Securities LLC - Managing Director

Excellent. Good morning, everyone, and welcome to the Hematology and Oncology Summit here at JMP Securities. It's my pleasure to introduce the Compugen team. Presenting for the Company is Anat, CEO. Eran is here as well. Welcome, team. Great to talk with you.

For those in the audience that may not know, Compugen would love for you to level set the playing field for us, maybe spend two to four minutes and give us an overview of Compugen. And operator, if you can go up about two slides, that would be great.

Anat Cohen;Dayag
Compugen Ltd. - President & CEO

Sure. Thank you, Reni, for inviting us for this conference. And I'll start with an overview. Compugen is a therapeutic discovery and development company. We discover new drug targets, and we develop first-in-class drugs to address these drug targets. And we're basing our discovery capabilities based on the computational discovery platform that we developed in the company, excelling in this process.

We discovered PVRIG

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot